In certain female neoplasms, higher GPER1 expression is associated with inferior prognosis and contributes to tumor development [11,12,13,14]; conversely, GPER1-dependent anti-tumor effects have been reported in other tumor types, as demonstrated by the tumor-inhibiting effects elicited by the selective small-molecule agonist G-1, or by its enantiomer LNS8801, in glioblastoma [15], Leydig tumor cells [16], uveal melanoma [17], and many others [18]. The gene discussed is GPER1; the disease is glioblastoma.